David Bolos
Hematology & Oncology · Los Angeles, CANPI 1134494321
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,311 of the $2,810 with a category attached, or 82.2%. It is spread thinly across 32 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 105 payments — averaging $26.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$301
- Seagen Inc.$252
- Johnson & Johnson$192
- AstraZeneca$170
- Merck$169
- Amgen$162
- plus $2K from 26 others
What the payments were for
- Food & beverage$2,31182%
- Education$49918%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 12 | $301 |
| Seagen Inc. | 9 | $252 |
| Johnson & Johnson | 5 | $192 |
| AstraZeneca(2 entities) | 9 | $170 |
| Merck | 6 | $169 |
| Amgen | 6 | $162 |
| Lilly USA, LLC | 3 | $144 |
| Regeneron Healthcare Solutions, Inc. | 4 | $121 |
| Pfizer | 7 | $115 |
| Sobi, Inc | 1 | $100 |
| AVEO Pharmaceuticals, Inc. | 1 | $99 |
| Genentech USA, Inc. | 4 | $91 |
| Incyte Corporation | 4 | $88 |
| Gilead(2 entities) | 3 | $87 |
| AbbVie | 3 | $82 |
| ADC Therapeutics America, Inc. | 3 | $80 |
| Sanofi | 3 | $69 |
| Bayer | 3 | $66 |
| Eisai Inc. | 3 | $61 |
| Foundation Medicine, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Karyopharm Therapeutics Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Geron Corporation | 1 | $31 |
| Genmab U.S., Inc. | 1 | $30 |
| Tersera Therapeutics LLC | 1 | $29 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
How this compares
$2,810 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- Dennis SlamonLos Angeles$3.1M
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.